Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04025632 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
A Phase 2 study, sponsored by Ra Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04025632 is a Phase 2 study that was terminated before completion, run by Ra Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT04025632, a Phase 2 study, was terminated before completion, sponsored by Ra Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.
Interventions
- OTHER Placebo
- DRUG zilucoplan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2021-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04025632
The ClinicalTrials.gov registry entry for NCT04025632 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ra Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04025632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04025632 about?
NCT04025632 is a clinical study titled "Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy". The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.
What is the current status of trial NCT04025632?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2019-11-07. Estimated completion is 2021-06-14.
What interventions are being tested in trial NCT04025632?
The interventions under investigation include: Placebo (OTHER), zilucoplan (DRUG).
Who is sponsoring clinical trial NCT04025632?
This trial is sponsored by Ra Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.